Effect of Vitamin D and Denosumab on Bone Remodelling in Women With Postmenopausal Osteoporosis
Status:
Completed
Trial end date:
2020-11-22
Target enrollment:
Participant gender:
Summary
Denosumab is a monoclonal antibody against RANKL ligand, which is used as an alternative
treatment for osteoporosis in patients who have a poor response to first-line antiresorptive
therapy. However, discontinuation of denosumab produces a rapid increase in bone turnover,
bone loss and potentially increased risk of multiple vertebral fractures.
Phase:
N/A
Details
Lead Sponsor:
Hospital Regional 1o de Octubre
Collaborators:
National Polytechnic Institute, Mexico Universidad Nacional Autonoma de Mexico